Survival and Recurrence Rates after Resection for Hepatocellular Carcinoma in Noncirrhotic Livers

Lang, Hauke; Sotiropoulos, Georgios C.; Brokalaki, Eirini I.; Schmitz, Klaus; Bertona, Christian; Meyer, Gabriele; Frilling, Andrea; Paul, Andreas; Malagó, Massimo; Broelsch, Christoph E.

doi:10.1016/j.jamcollsurg.2007.03.002

Cited by 130 publications

(78 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Incidence of ICC is rapidly increasing worldwide and accounts for 10%-20% of primary hepatic cancers (Gupta and Dixon 2017), and ICC is associated with a poorer 5-yr survival rate than HCC (Lang et al 2007;Rizvi and Gores 2013). We analyzed tumor/nontumor sample pairs from 10 ICC patients by RCseq and ∼40× WGS.…”

Section: A D C Bmentioning

confidence: 99%

L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis

et al. 2018

View full text Add to dashboard Cite

The retrotransposon Long Interspersed Element 1 (LINE-1 or L1) is a continuing source of germline and somatic mutagenesis in mammals. Deregulated L1 activity is a hallmark of cancer, and L1 mutagenesis has been described in numerous human malignancies. We previously employed retrotransposon capture sequencing (RC-seq) to analyze hepatocellular carcinoma (HCC) samples from patients infected with hepatitis B or hepatitis C virus and identified L1 variants responsible for activating oncogenic pathways. Here, we have applied RC-seq and whole-genome sequencing (WGS) to an Abcb4 (Mdr2)−/− mouse model of hepatic carcinogenesis and demonstrated for the first time that L1 mobilization occurs in murine tumors. In 12 HCC nodules obtained from 10 animals, we validated four somatic L1 insertions by PCR and capillary sequencing, including T F subfamily elements, and one G F subfamily example. One of the T F insertions carried a 3 ′ transduction, allowing us to identify its donor L1 and to demonstrate that this full-length T F element retained retrotransposition capacity in cultured cancer cells. Using RC-seq, we also identified eight tumor-specific L1 insertions from 25 HCC patients with a history of alcohol abuse. Finally, we used RC-seq and WGS to identify three tumor-specific L1 insertions among 10 intra-hepatic cholangiocarcinoma (ICC) patients, including one insertion traced to a donor L1 on Chromosome 22 known to be highly active in other cancers. This study reveals L1 mobilization as a common feature of hepatocarcinogenesis in mammals, demonstrating that the phenomenon is not restricted to human viral HCC etiologies and is encountered in murine liver tumors.

show abstract

Section: A D C Bmentioning

confidence: 99%

L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Interestingly, several reports have suggested that outcome after partial liver resection for NC-HCC is not influenced by tumor size [10,16,17]. Most recent series have indicated that partial liver resection for NC-HCC may result in 5-year survival rates varying between 40% and 70% and 5-year tumor-free survival rates varying between 30% and 50% [6,8,10,[16][17][18][19][20][21][22][23][24]. The prognosis for unresectable NC-HCC, however, is rather poor with an expected median survival time of about 30-40 weeks and a 5-year survival rate <3% [25,26].…”

Section: Partial Liver Resectionmentioning

confidence: 99%

Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis

Mergental¹,

Porte²

2010

Transplant International

View full text Add to dashboard Cite

Summary Hepatocellular carcinoma (HCC) arising in noncirrhotic and nonfibrotic liver (NC‐HCC) is a rare type of malignancy frequently found in healthy young individuals. Partial liver resection is the treatment of choice with expected 5‐year survival rates between 40% and 70%. As a result of absence of any symptom, a considerable number of patients are diagnosed when the malignancy has progressed to an advanced stage and the tumor has turned already unresectable. Some other patients suffer from intrahepatic recurrence after previous liver resection that cannot be re‐resected or locally ablated. In these situations, liver transplantation (LT) may be the only potentially curative treatment. The indication for LT in NC‐HCC patients, however, is not well established. The preliminary results of recent analysis of the European Liver Transplant Registry (ELTR) together with a literature review identified over 150 patients transplanted for NC‐HCC during the last 15 years. In contrast to the historical data, these studies showed 5‐year survival rates at 50–70% in well‐selected patients. Important determinants of poor outcome are macrovascular invasion, lymph node involvement, and time interval of <12 months when LT is used as rescue therapy for intrahepatic recurrence after a previous partial liver resection. Interestingly, outcomes after both liver resection and LT for NC‐HCC are much less influenced by tumor size than is the case with cirrhotic HCC. A large tumor size per se should, therefore, not to be seen as a strict contraindication for performing LT in patients with NC‐HCC.

show abstract

“…It is assumed that, among these, there are less cirrhotic cases than in developed countries [2]. Several studies have described the histopathological characteristics and outcomes of HCC arising in non-cirrhotic liver in Western countries [3,4,5,6]. However, such features and outcomes of Chinese operable HCC in non-cirrhotic liver have seldom been reported.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver

Huang

et al. 2008

Dig Surg

View full text Add to dashboard Cite

Background/Aims: Most hepatocellular carcinomas (HCC) are associated with cirrhosis. The clinicopathologic characteristics and outcomes of HCC present in non-cirrhotic livers are not well known in Chinese patients. This study was performed to explore the features of these patients and their outcomes after hepatectomy. Methods: 96 patients with histologically confirmed HCC in non-cirrhotic liver who underwent partial hepatectomy between 1995 and 2001 in our cancer center were reviewed. A retrospective analysis of the clinicopathologic features was performed, and survival of patients was analyzed by the Kaplan-Meier method and Cox regression model. Results: Operative mortality and morbidity were none and 8.3% (8/96), respectively. Postoperative overall survival (OS) rates at 1, 3, 5 and 10 years were 84.4, 62.5, 47.9 and 38.2%, respectively, with a median OS of 57 months. Disease-free survival (DFS) rates at 1, 3, and 5 years were 56.3, 39.6, and 33.3%, respectively, with a median DFS of 18 months. TNM stage was an independent prognostic factor for both OS and DFS of non-cirrhotic HCC. Operative blood loss was an independent prognostic factor for OS and DFS of patients who received curative resection. Conclusion: Curative partial hepatectomy was an effective and safe treatment for non-cirrhotic HCC. Aggressive local therapies were recommended for patients with intrahepatic recurrence.

show abstract

Survival and Recurrence Rates after Resection for Hepatocellular Carcinoma in Noncirrhotic Livers

Cited by 130 publications

References 31 publications

L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis

L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis

Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis

Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver

Contact Info

Product

Resources

About